Triluma Cream is a prescription topical therapy specifically formulated for melasma of the face, combining fluocinolone acetonide 0.01% (a corticosteroid), hydroquinone 4% (a skin lightener), and tretinoin 0.05% (a retinoid) for a multi‑targeted approach to pigment reduction and improved skin tone. Used once daily at night, Triluma reduces inflammation, lightens dark patches, and accelerates cell turnover, delivering visible improvements within 3–8 weeks of regular use, alongside strict sun protection. Dermatologists favor this triple‑action blend for its proven results and convenience in managing moderate to severe melasma.